Commendable Lung Cancer Treatment Progress Over Latest Decade: 2010-2020

2010 aroused a new wave of hope for lung cancer patients after decades of failed research. Treatment progressed its highest peak in the mid-2010s and then made several advances in the last five years, outweighing all the previous five decades betterment. Lung cancer treatment has become more accessible and useful. Treatment for lung cancer in Delhi NCR is applauded for keeping up with the new technologies and breakthroughs in lung cancer treatment and making it one of the best cities for lung cancer treatment. 

The field of study is rushing towards the 2020s, and it seems an excellent time to see how much lung cancer treatment has evolved over the past decade. For the past several decades, lung cancer has been the most common cancer globally, with the highest proportion of all cancer-related deaths. 

Cancer doctor or Oncologists worldwide, including the best lung cancer doctor in Delhi NCR, worked hard to find a responsive lung cancer treatment. Before that, the procedure of open lobectomy was implemented. According to a survey, the statistics concluded that people who underwent VATS lobectomy experienced fewer complications than those who underwent open lobectomy (32.8% vs. 44.3%) and shorter lengths of stay (4 days vs. five days). Some centers have implemented other techniques such as segmentectomy, single-port VATS, and robotic-assisted thoracic surgery, with promising outcomes.

Radiotherapy has become more precise

People with early-stage non-small cell lung cancer cannot undergo surgery. Therefore, stereotactic ablative radiotherapy (SABR) gives promising results as an alternative. With its commendable success in the treatment of NSCLC, researchers are focusing on using SABR therapy for early-stage disease. Though the treatment was introduced in the early 2000s, the treatment improved a lot in the later decade as it pumped up the overall survival rates. 

Molecular testing increasing life expectancy by 1 year

After discovering oncogenic drivers in lung cancer, the field embraced molecular testing as a fundamental tool to guide and individualize the individual patient’s treatment. A study conducted showed the importance of screening for driver mutations as a standard component of the diagnostic workup for NSCLC. Patients who received targeted therapy survived an average lifespan of 3.5 years as opposed to 2.4 years in oncogenic drivers.

Systemic Therapy pumping numbers from 20% to 23%.

Ten years ago, only 20% of lung cancer patients lived beyond five years after diagnosis. Today, there are 20 new agents, targeted therapies, checkpoint inhibitors, and anti-angiogenic agents that have transformed the treatment landscape. The overall survival (OS) rates are beginning to move upwards. In 2016, the OS rate had reached 23.5%, and oncologists worldwide, including the best cancer specialist in Delhi, expect it to move even higher. 

After introducing immune inhibitors in 2015 made a milestone in lung cancer treatment, it quickly went on to be among the first-line settings and other therapies. Since then, immunotherapy has become standard care for patients with advanced NSCLC for two years to maintain response.

Anti-angiogenic therapy welcomes new medicines

Before 2014, only one anti-angiogenic agent approved NSCLC treatment until Ramucirumab introduction, which changed the whole treatment landscape. According to a study, Ramucirumab had superior outcomes compared with patients who received other treatments. The patients’ overall survival taking Ramucirumab is 10.5, whereas patients with different treatment are 9.1 months, and mean progression-free survival (4.5 vs. 3.0 months). 

Palliative therapy slashing depressive symptoms by half

Palliative care has a vital role in lung cancer treatment, and a lot of work has been done on it in the past decade. According to a research, it was seen that people undergoing palliative care compared to standard care had a better quality of life on the functional assessment of cancer therapy lung scale ( 98.5 vs. 91.5), fewer depressive symptoms (16% vs. 38%), and longer mean overall survival rate. Moreover, palliative therapy is often recommended as a standard procedure for disease management. 

Targeted therapy with higher resistance

Targeted therapy was always seen to have a lot of potential in it for fighting against NSCLC. In the 2010s, research on targeted therapy was done on such levels that various agents were introduced with higher genetic resistance barriers. 

With advanced bioinformatics technology and modern molecular biology, the treatment is beneficial for patients who have cancer. Even in India, a cancer specialist in Delhi, like Dr. Manish Singhal, supports this treatment and has already switched to this approach. With the most advanced technology and this beneficial approach, the best oncologist in Delhi NCR, like Dr. Manish Singhal, has successfully made many lung cancer patients’ lives more comfortable and better with the treatment. Visit here and find solutions and motivation regarding aching cancers.

ALSO READ: ASCO 2020 Discussion On Lung Cancer: Finding And Recent Drug Approvals